Global pharmaceutical company Mylan has announced the US launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.
It is intended for use in these indications with aspirin. The safety and effectiveness have not been established in patients with acute coronary syndromes who are not undergoing PTCA or PCI.